The company, which provides respiratory and acute care systems and products for the treatment of obstructive sleep apnoea reported an operating profit of $170.1 million for the period, up 18.6% on the $143.5 million reported in the previous corresponding period (pcp).
The reported profit of $113.2 million was up 17% on the $97.1 million reported in the pcp.
Operating revenue was also a record at $652.3 millon, 8% above the previous year or 13% growth in constant currency.
Chief executive Michael Daniell said the company had exceeded its earnings guidance provided in November with robust revenue growth in both major product groups, a continuation of gross margin and expansion and through operating leverage, and despite a $26.7 million reduction in foreign exchange hedging gains compared to the pcp.
A final dividend of 8c per share was a 14% increase on the previous year.
''We are pleased with our record results, which demonstrate success of our consistent growth strategy. Our medical devices are designed to increase the effectiveness and efficiency of care and we estimate our products were used in treatment on more than 10 million patients during the year.''
Each of the company's major product groups reported record operating revenue.
Revenue for the respiratory group grew 9% to $368.2 million and the apnoea group revenue grew 8% to $291.1 million.
The proportion of the company's revenue generated from recurring items, such as consumables and accessories, continued to increase and accounted for 81% of core operating revenue, Mr Daniell said.
Last week, a positive clinical trial result was published in the New England Journal of Medicine.
The randomised controlled trial, which included 310 patients and was conducted in 23 intensive care units in France and Belgium, found a significant reduction in mortality for acute hypoxemic respiratory failure patients treated with Optiflow nasal high flow therapy compared to standard oxygen therapy or non-invasive ventilation.
The company had established an expanded distribution centre in the United States and was doubling the size of its US hospital sales and support team, he said.
The investment being made during the next six months would ensure F&P had the resources to serve its hospital customers.
''We continue to focus on our strategy of continually improving our products, servicing more patient groups, extending our range of products and growing our international presence.
''We believe this strategy will continue to deliver robust revenue growth in the current year.''
The company provided first-time 2016 guidance for revenue of about $750 million and reported profit of between $125 millon and $130 million.
At a glance
• 17% growth in reported profit to record $113.2 million
• Operating profit increased nearly 19% to $170.1 million.
• Final dividend of 8cps will be paid, up 14% on the pcp
• 8% growth in operating revenue to record $672.3 million.
• Operating revenue in 2016 likely to be about $750 million
